Oppenheimer started coverage on shares of Compugen (NASDAQ:CGEN) in a report released on Thursday, TipRanks reports. The brokerage issued a buy rating and a $19.00 price target on the biotechnology company’s stock.
CGEN has been the subject of several other reports. BidaskClub cut shares of Compugen from a hold rating to a sell rating in a report on Tuesday, July 28th. SVB Leerink assumed coverage on Compugen in a report on Thursday, May 7th. They set an outperform rating and a $15.00 price target on the stock. SunTrust Banks raised their price target on Compugen from $16.00 to $22.00 and gave the stock a buy rating in a research note on Tuesday, April 28th. Roth Capital started coverage on Compugen in a report on Wednesday, April 22nd. They issued a buy rating and a $28.00 target price on the stock. Finally, ValuEngine downgraded shares of Compugen from a buy rating to a hold rating in a report on Thursday, July 2nd. One investment analyst has rated the stock with a sell rating, one has given a hold rating and eight have assigned a buy rating to the stock. The company has a consensus rating of Buy and a consensus target price of $18.75.
CGEN opened at $14.41 on Thursday. The firm has a market capitalization of $985.93 million, a P/E ratio of -37.92 and a beta of 2.84. The company has a fifty day moving average price of $15.10 and a 200-day moving average price of $11.53. Compugen has a one year low of $2.96 and a one year high of $17.85.
Compugen (NASDAQ:CGEN) last announced its quarterly earnings data on Thursday, July 30th. The biotechnology company reported ($0.08) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.10) by $0.02. Research analysts forecast that Compugen will post -0.42 earnings per share for the current year.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Steward Partners Investment Advisory LLC lifted its holdings in Compugen by 700.0% during the first quarter. Steward Partners Investment Advisory LLC now owns 4,000 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 3,500 shares in the last quarter. Citigroup Inc. raised its position in shares of Compugen by 688.7% during the 4th quarter. Citigroup Inc. now owns 5,521 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 4,821 shares during the period. Harel Insurance Investments & Financial Services Ltd. purchased a new position in shares of Compugen during the 2nd quarter valued at $135,000. SG Americas Securities LLC bought a new position in Compugen in the 2nd quarter worth $150,000. Finally, Cambridge Investment Research Advisors Inc. purchased a new stake in Compugen in the 1st quarter worth $80,000. Institutional investors own 46.56% of the company’s stock.
Compugen Company Profile
Compugen Ltd., a therapeutic discovery company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel and Europe. The company's therapeutic pipeline consists of immuno-oncology programs against novel drug targets in the areas of unmet medical needs in various cancer types and patient populations.
Featured Article: Fundamental Analysis and Choosing Stocks
Receive News & Ratings for Compugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen and related companies with MarketBeat.com's FREE daily email newsletter.